CollPlant announced that two patients have been recruited for the clinical trial
expected to extend for up to one year, designed to evaluate the safety of its VergenixWD dressing, fabricated using CollPlant’s proprietary recombinant human collagen.
VergenixWD is a wound healing sheet, designated to treat, using standard and accepted procedures, acute and chronic wounds, such as burns, pressure sores, venous ulcers, diabetic ulcers, second-degree burns, abrasions, surgical incisions, hemorrhaging wounds, and others. Similar products are available, but contain animal- or cadaver-derived collagen. According to current and public market surveys, the annual market size of wound healing for which VergenixWDTM has been formulated, stands at 5 billion dollars, and is constantly rising in correlation with the aging world population and with the respective increasing number of chronic wounds requiring medical attention.
CollPlant Ltd. is a medical devices firm established in 2004 to focus on advancing regenerative medicine through its cutting edge technology designed to generate and process proprietary recombinant human collagen, among other patent-protected recombinant proteins. CollPlant is developing a broad spectrum of biomaterials for a wide variety of medical markets, including orthopedics, wound healing, cardiology and general surgery.